Author
KIMURA, KAYOKO - IOWA STATE UNIVERSITY | |
Baker, Amy | |
Lager, Kelly | |
ROTH, JAMES - IOWA STATE UNIVERSITY | |
Kehrli Jr, Marcus |
Submitted to: Journal of Immunology
Publication Type: Abstract Only Publication Acceptance Date: 2/28/2006 Publication Date: 4/1/2006 Citation: Kimura, K., Vincent, A.L., Lager, K.M., Roth, J.A., Kehrli, Jr., M.E. 2006. Assay for proliferation of porcine PBMC with Oregon Green 488 and its application for evaluation of T cell responsiveness to swine influenza virus [astract]. Journal of Immunology Supplement. 176:S118. Paper No. 59.12. Interpretive Summary: Technical Abstract: Cell proliferation assays are a useful method to analyze cell-mediated immunity (CMI) to microbial antigens. In order to define T cell responsiveness to virus antigens in pigs, we have developed flow cytometric assays for porcine peripheral blood mononuclear cell (PBMC) proliferation using Oregon Green 488, an analog of carboxy-fluorescein diacetate, succinimidyl ester. Oregon Green 488 dye dilution and 5-bromo-2-deoxyuridine incorporation were very well correlated (r = 0.7307) after stimulation of porcine PBMC to undergo mitosis. We applied this technique together with intracellular IFN-gamma, and CD25 cell surface expression assays in order to determine recall responses of PBMC to swine influenza virus (H1N1) (SIV) antigen after vaccination (pigs primed and boosted with a killed virus vaccine, 3 weeks apart) and challenge (2 weeks after the second vaccination). All three parameters increased with in vitro virus stimulation of PBMCs obtained from vaccinated pigs at five days following live SIV challenge but not in unchallenged control pigs. Vaccinated and challenged pigs had the strongest CMI responses whereas pigs that were either vaccinated or challenged with live virus alone, had weaker responses. Pigs challenged without vaccination had the lowest expression of CD25 at five days after challenge. These techniques are useful to evaluate antigen specific CMI responses in pigs to understand pathogenesis and protective immunity after vaccination and/or infection with SIV. |